In a recent meta-analysis and systematic review of eight studies, the pooled OR was 2.10 (95% CI: 1.70–2.60) for ALK+ NSCLC and 3.15 (95% CI: 1.83–5.43) for ROS1+ NSCLC [27]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.